Burden of early, advanced and metastatic breast cancer in The Netherlands

DSpace/Manakin Repository

Burden of early, advanced and metastatic breast cancer in The Netherlands
 
Vondeling, G. T.; Menezes, G. L.; Dvortsin, E. P.; Jansman, F. G.A.; Konings, I. R.; Postma, M. J.; Rozenbaum, M. H.
(2018) BMC Cancer, volume 18, issue 1, pp. 1 - 11
(Article)
Abstract
Background: The aim of this study was to estimate the total economic and health related burden of breast cancer in the Netherlands. Methods: Data on incidence, prevalence, mortality and survival were extracted from the Dutch National Cancer Registry and were used to calculate the economic and health related burden of ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Breast cancer, burden, costs incidence, prevalence, mortality, early advanced metastatic, Prevalence, Prognosis, Follow-Up Studies, Humans, Middle Aged, Cost of Illness, Incidence, Young Adult, Breast Neoplasms/economics, Aged, 80 and over, Adult, Female, Registries, Netherlands/epidemiology, Quality-Adjusted Life Years, Survival Rate, Tumor Burden, Carcinoma, Ductal, Breast/economics, Carcinoma, Intraductal, Noninfiltrating/economics, Adolescent, Aged, Breast cancer burden costs incidence prevalence mortality early advanced metastatic, Genetics, Oncology, Cancer Research, Research Support, Non-U.S. Gov't, Journal Article
DOI: https://doi.org/10.1186/s12885-018-4158-3
ISSN: 1471-2407
Publisher: BioMed Central
Note: Funding Information: BoD: Burden of Disease; CPI: Customer Price Index; DALYs: Disability Adjusted Life Years; DCIS: Ductal Carcinoma In Situ; ESR: European age Standardized Rates; HER2 + : Human Epidermal Growth factor 2 Positive; HR + : Hormone Receptor Positive; IARC: International Agency for Research on Cancer; ICD-O: International Classification of Diseases for Oncology; IKNL: Netherlands Comprehensive Cancer Organization; NCR: National Cancer Registry; RIVM: National Institute for Public Health; TNM: Tumour Node Metastasis; YLD: Years Lived with Disability; YLL: Years of Life Lost due to premature mortality Funding Information: Data extraction and data analysis was funded by Pfizer (Reference number 8501115515). Pfizer did not influence the study design, the data collection, the data analysis, the interpretation of data and the writing of the manuscript. Funding Information: 9. National Institute for Public Health and the Environment / Ministry of Health, Welfare and Sport. National Evaluation of breast cancer screening in the Netherlands (facts and figures). https://www.rivm.nl/en/Documents_ and_publications/Common_and_Present/Publications/Disease_prevention_ and_healthcare/breastcancer_screening/National_evaluation_of_breast_ cancer_screening_in_the_Netherlands. Accessed 3 Oct 2014. Funding Information: Breast cancer incidence, prevalence, survival and mortality data between 1990 and 2014 were obtained from the Netherlands Comprehensive Cancer Organization (IKNL) and the National Cancer Registry (NCR) [10] .As survival data within this database is generated in cohorts, most recent 10-year survival was available until 2009. Additionally, data was available for up to 4-year survival in the latest cohort (2010–2013). Tumors in this registry are coded according to the International Classification of Diseases for Oncology (ICD-O). Regarding multiple primary cancers, the registry follows the guidelines developed by the International Agency for Research on Cancer (IARC) and the International Association of Cancer Registries (IACR). In this study we differentiate between early, locally advanced and metastatic breast cancer based on the Tumour Node Metastasis (TNM) classification and IACR guidelines [11, 12] .Stage 0 (DCIS) and Stage I were defined as early breast cancer, stages II to III as locally advanced breast cancer, and stage IV was labeled as metastatic breast cancer. In the performed analyses (see below), the results are reported per separate stage where possible. This distinction was made based on the differences in treatment guidelines with recommendations ranging from breast-conserving surgery to mastectomy, radiation therapy, chemotherapy, hormone therapy, or a combination of different treatments in stage IV [13, 14]. Publisher Copyright: © 2018 The Author(s).
(Peer reviewed)